China SXT Pharmaceuticals (SXTC) Liabilities and Shareholders Equity (2018 - 2025)

China SXT Pharmaceuticals' Liabilities and Shareholders Equity history runs 8 years deep, the most recent figure standing at $26.4 million for Q3 2025.

• In Q3 2025, Liabilities and Shareholders Equity fell 14.98% year-over-year to $26.4 million; the TTM figure through Sep 2025 stood at $102.1 million (up 3.94% YoY), while the FY2025 annual figure was $21.7 million, down 6.33% from the prior year.
• Liabilities and Shareholders Equity was $26.4 million for Q3 2025 at China SXT Pharmaceuticals, up from $21.7 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $34.5 million in Q1 2021 to a low of $14.6 million in Q3 2023.
• Historically, Liabilities and Shareholders Equity has averaged $25.9 million across 5 years, with a median of $24.7 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Liabilities and Shareholders Equity plunged 34.23% in 2023, then surged 112.49% in 2024.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $22.7 million in 2021, then retreated by 2.16% to $22.2 million in 2022, then slumped by 34.23% to $14.6 million in 2023, then soared by 112.49% to $31.0 million in 2024, then dropped by 14.98% to $26.4 million in 2025.
• The last three Liabilities and Shareholders Equity figures came in at $26.4 million (Q3 2025), $21.7 million (Q1 2025), and $31.0 million (Q3 2024), per Business Quant data.